Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mangoceuticals (MGRX) Other Operating Expenses (2023 - 2025)

Historic Other Operating Expenses for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $7.3 million.

  • Mangoceuticals' Other Operating Expenses rose 45300.34% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year increase of 14737.02%. This contributed to the annual value of $5.4 million for FY2024, which is 1547.29% down from last year.
  • Per Mangoceuticals' latest filing, its Other Operating Expenses stood at $7.3 million for Q3 2025, which was up 45300.34% from $4.1 million recorded in Q2 2025.
  • Over the past 5 years, Mangoceuticals' Other Operating Expenses peaked at $7.3 million during Q3 2025, and registered a low of $903710.0 during Q4 2024.
  • Over the past 3 years, Mangoceuticals' median Other Operating Expenses value was $1.8 million (recorded in 2023), while the average stood at $2.5 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first tumbled by 5212.86% in 2024, then skyrocketed by 45300.34% in 2025.
  • Mangoceuticals' Other Operating Expenses (Quarter) stood at $1.9 million in 2023, then plummeted by 52.13% to $903710.0 in 2024, then skyrocketed by 705.84% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q3 2025, $4.1 million for Q2 2025, and $3.4 million during Q1 2025.